- The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

Study: Combination of ASCT and Bortezomib Can Increase Survival

Cancers Originating on Left Side of Colon Associated with Longer Survival, Study Says

FDA Grants Approvals to Tecentriq, Opdivo, Imbruvica, Lenvima

Alecensa Reduces Death Risk by 66 Percent in Phase III Trial

Phase Ib Trial Shows 40 Percent of Patients Receiving Keytruda Alive After 36-Month Follow Up

CCL May - Mesothelioma WT1 Vaccine Doubles PFS in Phase II Trial

LEE011 Meets Primary Endpoint, Improves PFS in Phase III Trial

Study: Precision Medicine Yields Better Outcomes in Phase I Clinical Trials

Study: Early Palliative Care Provides Benefits for Family Caregivers of Patients

CCL May - NCI CTEP-Approved Trials for the Month of May

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login